Clinical Trial Update: A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating lenvatinib plus pembrolizumab in hepatocellular carcinoma has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Eisai Co., Ltd. | Conditions: Hepatocellular Carcinoma | Phase 1 | Status: COMPLETED | Results posted: 2020-12-31